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Abstract
Background: Extracellular human sulfatases modulate growth factor signaling by alteration of the heparin/heparan
sulfate proteoglycan (HSPG) 6-O-sulfation state. HSPGs bind to numerous growth factor ligands including fibroblast
growth factors (FGF), epidermal growth factors (EGF), and vascular endothelial growth factors (VEGF), and are
critically important in the context of cancer cell growth, invasion, and metastasis. We hypothesized that sulfatase
activity in the tumor microenvironment would regulate tumor growth in vivo.
Methods: We established a model of stable expression of sulfatases in the human breast cancer cell line MDA-MB-
231 and purified recombinant human Sulfatase 2 (rhSulf2) for exogenous administration. In vitro studies were
performed to measure effects on breast cancer cell invasion and proliferation, and groups were statistically
compared using Student’s t-test. The effects of hSulf2 on tumor progression were tested using in vivo xenografts
with two methods. First, MDA-MB-231 cells stably expressing hSulf1, hSulf2, or both hSulf1/hSulf2 were grown as
xenografts and the resulting tumor growth and vascularization was compared to controls. Secondly, wild type
MDA-MB-231 xenografts were treated by short-term intratumoral injection with rhSulf2 or vehicle during tumor
growth. Ultrasound analysis was also used to complement caliper measurement to monitor tumor growth. In vivo
studies were statistically analyzed using Student’s t test.
Results: In vitro, stable expression of hSulf2 or administration of rhSulf2 in breast cancer cells decreased cell
proliferation and invasion, corresponding to an inhibition of ERK activation. Stable expression of the sulfatases in
xenografts significantly suppressed tumor growth, with complete regression of tumors expressing both hSulf1 and
hSulf2 and significantly smaller tumor volumes in groups expressing hSulf1 or hSulf2 compared to control
xenografts. Despite significant suppression of tumor volume, sulfatases did not affect vascular density within the
tumors. By contrast, transient exogenous treatment of MDA-MB-231 xenografts with rhSulf2 was not sufficient to
inhibit or reverse tumor growth.
Conclusion: These data indicate thatin vivo progression of human breast cancer xenografts can be inhibited with
sulfatase expression, and therapeutic effect requires constant delivery at the tumor site. Our results support a direct
effect of sulfatases on tumor growth or invasion, rather than an effect in the stromal compartment.
Background
Breast cancer is the leading cause of invasive cancer in
women. The lifetime risk of breast cancer in women is
estimated at 1 in 8 (13% of women) [1]. Factors that
decrease cancer cell invasion and tumor growth have the
potential for translation into novel therapeutic approaches
for lessening breast cancer morbidity and mortality.
Extracellular sulfatases appear to have a significant role in
cancer biology. Heparan sulfate-like glycosaminoglycans,
along with structural proteins, are important regulators at
the cell surface-extracellular matrix (ECM) interface [2,3].
Human Sulfatase 1 (hSulf1) and Sulfatase 2 (hSulf2) are
heparan sulfate 6-O-endosulfatases, a family of secreted
enzymes that are either localized on the cell surface
or released into the ECM. HSulf1 and hSulf2 cleave 6-O-
sulfate moieties of heparan sulfate, thereby affecting com-
position and function of the glycosaminoglycans. Because
glycosaminoglycans regulate cytokine signaling, heparan
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naling events rely on activity of sulfatase enzymes. HSPGs
are key components of the ECM that are involved in
tumor progression by regulation of growth factor signaling
pathways. Most of the molecular events associated with
tumor growth, neovascularization, and metastases are
influenced by interactions between cells and their ECM.
T h e r ei sm o u n t i n ge v i d e n c ef o rt h er o l eo ft w os e c r e t e d
human extracellular sulfatases, hSulf1 and hSulf2, in mod-
ulating the growth factor signaling pathways needed for
tumor angiogenesis and progression [4]. However, much
of the data that exists on the role of hSulf1 and hSulf2 is
context dependent to distinct cancer types and cellular
environment [5-8].
HSulf1 and hSulf2 have overlapping yet distinct roles
both in development and cancer progression. Mouse
knockout models of Sulfatase 1 or Sulfatase 2 display a
normal phenotype by nearly all criteria examined [9].
Combined knockout of Sulfatase 1 and 2 in mice, how-
ever, leads to ~50% neonatal lethality and ~80% postna-
tal lethality with prominent skeletal and renal
developmental defects [9]. Cancer models also display
evidence of context-specific sulfatase activity. HSulf1
expression is decreased in 82% of hepatocellular carci-
noma (HCC) cell lines, leading to increased HSPG sulfa-
tion, enhanced FGF-mediated and hepatocyte growth
factor (HGF)-mediated signaling, and increased cell
growth [10]. Forced expression of hSulf1 decreases sul-
fation, inhibits growth factor signaling, and sensitizes
HCC cells to chemotherapeutic apoptosis [10]. While
previous study of overexpression of hSulf1 in the estro-
gen receptor negative MDA-MB-468 cell line has been
shown to decrease tumor burden in athymic nude mice
in vivo, few data are available regarding the therapeutic
role of forced expression of hSulf2 on in vivo tumor
burden.
We hypothesized that hSulf2 might have an effect in
inhibiting cancer cell growth and invasion in vitro and
in vivo. In order to further understand the role of
hSulf2 in breast cancer, we chose the human breast can-
cer cell line MDA-MB-231, a well characterized and
established model for human breast cancer growth.
Although reports in the literature describe variable
levels of sulfatase expression in MDA-MB-231 cells
[6,11], we did not detect endogenous expression of
hSulf1 or hSulf2 in our MDA-MB-231 population, using
RT-PCR. We therefore chose the MDA-MB-231 cell
line for gain-of-function studies by creating transfected
pools that stably express human sulfatases. Given that
hSulf1 has been established as an inhibitor of tumori-
genesis [8], we used overexpression of hSulf1 as a posi-
tive control and also tested hSulf1 in conjunction with
hSulf2. For delivery of rhSulf2, intratumoral injection
was chosen as the initial approach for two reasons. The
first was based on in vivo data about the anticipated
effect of hSulf2 on the stromal component. The second
was based on attempt to avoid first pass metabolism
through the liver and deliver maximal protein to the
tumor site.
In vitro studies provide evidence that expression or
delivery of hSulf2 decreases proliferation and tumor cell
invasion through the ECM. In vivo studies show that
hSulf2 expression is effective in suppressing xenograft
growth. In our system, this effect appears to be indepen-
dent of an angiogenic effect, because tumor growth was
significantly suppressed without dramatic changes in the
angiogenic response to the xenograft. Further studies
are needed to better characterize and validate the role of
hSulf2 in inhibiting tumor growth and progression in
vivo.
Methods
Materials
FGF2 and HB-EGF-2 were obtained from Sigma
(St. Louis, MO). EGFR inhibitor PD153035 was obtained
from EMD Biosciences (San Diego, CA). Total ERK and
phospho-ERK antibodies were purchased from R&D
Systems (Minneapolis, MN). Growth factor reduced
Matrigel was obtained from BD Biosciences (San Jose,
CA). CD31 (PECAM) antibody was obtained from BD
Pharmingen. Ki-67 antibody was obtained from Ventana
Corporation (Tucson, AZ).
Recombinant protein production
An expression vector with full-length human Sulfatase
2 cDNA was transfected into HT1080 cells by electro-
poration. HT1080 cells were grown and maintained in a
serum-free DMEM/F-12 based custom media (Invitro-
gen, Carlsbad, CA) at 37°C in a 5% CO2 incubator.
Transfection with a neomycin resistance cassette
allowed for the selection of stably transfected clones.
Clones were expanded and cell supernatants examined
for expressed hSulf2 protein. Conditioned medium was
processed by copper binding followed by gel filtration.
Selected gel filtration fractions were pooled and dialyzed
against 20 mM sodium phosphate, 0.5 M NaCl, 10% gly-
cerol, 0.5 mg/ml Pefabloc at pH = 7.5. RhSulf2 was
visualized by Coomassie staining (GelCode Blue Stain
Reagent, Pierce, Rockford, IL) of 8-16% tris-glycine
SDS-PAGE gels (Invitrogen, Carlsbad, CA). Glycerol and
Pefabloc were removed by dialysis into a final buffer of
500 mM NaCl, 20 mM NaPO4 pH = 7.
Cell Culture
MDA-MB-231 (HTB-26) and MDA-MB-435 S (HTB-
129) cell lines were obtained from ATCC. MDA-MB-231
cells stably expressing control vector, human Sulfatase 1
(hSulf1), human Sulfatase 2 (hSulf2), or a combination of
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Specific clones of transfected hSulf1 and hSulf2 cells
were selected based on the strength of respective hSulf
protein and phenotypic validation in vitro of reduced cell
proliferation and migration. MDA-MB-231 and MDA-
MB-435 S cells for in vitro experiments were cultured in
minimal essential media (MEM) supplemented with 10%
F B S ,2m ML - g l u t a m i n ea n d0 . 0 1m g / m li n s u l i na t3 7 ° C ,
5% CO2. For the invasion assay, cells were cultured in
MEM supplemented with 5% charcoal-stripped FBS, 2
mM L-Glutamine and 0.01 mg/ml insulin 24 hours prior
to assay. On the day of the assay, cells were suspended in
migration media (serum-free basal media) and placed in
the top well of invasion chambers (Chemicon ECM554).
Chemoattractant (10% FBS) was placed in the lower
chamber in migration media. Cells were allowed to
invade for 24 hours at 37°C. Cells were harvested and
invasion rate was determined according to manufac-
turer’s protocol. For MTT assays, cells were seeded at
40,000 cells/cm
2 into 48-well plates in complete growth
medium. After 24 h, cells were rinsed and treated with
either rhSulf2 formulation buffer or with varying concen-
trations of rhSulf2. On days 1, 2 and 3, 5 mg/ml MTT
was added to the cells for 4 hours at 37°C. After the incu-
bation the media was aspirated, DMSO was added and
the OD at 570 nm was measured. Cell count and viability
was assessed using a Cell sorter (Cedex, Innovatis-Roche,
Germany). For tumor xenograft implantation, MDA-MB-
231 cell populations expressing human sulfatases were
cultured in MEM supplemented with 10% FBS, 1% non-
essential amino acids, and 0.5% gentamicin.
RT-PCR
Primers used for hSulf1 were S1fw 5′ ACGGGG-
GAGCTGGAGAATACTTAC 3′/S1rev 5′ GCCACT
TCTGCCCCGGTTGTTCAC 3′, for hSulf2 there were
2 sets of primers S2fw 5′ CCGCCCAG CCCCGAAACC
3′/S2rev 5′ CTCCCGCAACAGCCACACCTT 3′ as well
as S2fw 5′ CTCCGTTTTCCT TTGTGAGC 3′/S2rev 5′
GAATTTGCAACTGGCTT CCT 3′ and for b-actin 5′
AGAAAATCTGGCACCACACC 3′/5′ CTCCTTAATGT
CACGCACGA 3′ was used. One Step RT-PCR kit (Invi-
trogen, Carlsbad, CA) was used according to manufac-
turer’s instruction for sulfatase determination in cells.
Stable transfectant tumor xenograft production
All animal studies were performed in accordance with
established protocols approved by the Maine Medical
Center Institutional Animal Care and Use Committee.
Three groups of stably transfected MDA-MB-231 cells
were prepared for in vivo tumor xenograft growth in
comparison with control vector-transfected cells: cells
expressing both hSulf1 and hSulf2, only hSulf1, or only
hSulf2. Thirty-two litter-matched female NCr
homozygous nu/nu mice (Taconic) at nine weeks of age
were chosen as xenograft hosts. These were randomized
by cage into four groups of eight mice each. The first
group was injected with the control vector-transfected
cells, the second group was injected with cells expres-
sing both hSulf1 and hSulf2, the third group was
injected with cells expressing only hSulf1, and the fourth
group was injected with cells expressing only hSulf2.
Injections were placed subcutaneously into the left flank
and contained 5 million MDA-MB-231 cells suspended
in 200 μl of PBS. Measurements were obtained by cali-
per length and width measurements at 2-3 day intervals
for the duration of the experiment. Tumor volume was
calculated from the pi-based ellipsoid volume formula
π/6*length*width*height [12], assuming ellipsoid shape
with equal width and height. The average value and
standard deviation are based on calculated tumor
volumes from the eight mice in each group. Tumor
xenografts recovered from mice were fixed in 4% paraf-
ormaldehyde and embedded in paraffin. Tissue sections
were stained with Masson’s trichrome staining for visua-
lization of collagen, CD31 (PECAM) staining for visuali-
zation of tumor vasculature, or Ki-67 staining for
mitotic index. Average mitotic index quantification was
obtained by counting 5 high-power fields per tumor
using ImageJ software [13].
Tumor xenograft production for exogenous therapy with
purified recombinant human Sulfatase 2 (rhSulf2)
For production of tumor xenografts for the exogenous
treatment arm of the study, 200 μl of a 1:1 Matrigel:buf-
fer suspension containing 8.5 million MDA-MB-231
cells was subcutaneously injected into the left flank of
32 female litter-matched nude mice. Four additional
female litter-matched nude mice were injected with 200
μl of the Matrigel:buffer suspension only, and four
remaining female litter-matched nude mice were left
un-manipulated as experimental controls. Following a
48 hour window to allow establishment of tumor xeno-
grafts in mice injected with tumor cells, intratumoral
injections of rhSulf2 were administered to the 16 mice
randomized to the treatment group. Each injection con-
t a i n e d0 . 1m gr h S u l f 2b a s e do na ne s t i m a t e d5m g / k g
dose in an average 20 g nude mouse. An equal volume
of control buffer vehicle was administered intratumo-
rally to the 16 mice in the treatment control group.
High resolution ultrasound imaging of tumor xenografts
Mice were anesthetized by inhaled isoflurane prior to
ultrasound scanning with a VisualSonics Vevo 770 high-
resolution imaging system. Tumors were initially
scanned free hand to establish approximate tumor size
and morphology. Images for tumor reconstruction were
acquired by 3D motor stage in alignment with the long
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cessed on a high-definition monitor for obtaining volu-
metric measurements. Successive tracings of tumor
contour were taken which enabled the computer soft-
ware to generate a 3D image and volume for each
tumor. For comparison to external caliper measure-
ments, × axis (length) was assigned to the longest visible
dimension of the tumor. From there, y axis (width) was
assigned to 90 perpendicular axis, and Z axis (height)
assigned to tumor depth. The pi-based ellipsoid equa-
tion π/6*length*width*height has previously been vali-
dated as the best equation for estimating subcutaneous
tumor size in athymic nude mice [12]. However, track-
ing of tumor size by estimation of standard caliper mea-
surements in vivo involves the assumption of width
equaling depth, given that only two dimensions can be
measured in vivo. Here we report methodology for mak-
ing these measurements more precise by non-invasively
capturing depth component through high resolution
in vivo ultrasound imaging.
Statistical Analysis
Statistical analyses were performed using Student’st
test, with a significant difference determined as p < 0.05.
Where appropriate, data are represented as means ± SD.
Results
HSulf2 expression in MDA-MB-231 cells
Most of the recent data have been focused on the effect
of hSulf1 in different tumor cell lines. HSulf1 over-
expression in cells has been reported to inhibit tumor
formation in vitro and in vivo.W ew e r ei n t e r e s t e di n
understanding the role of the related protein hSulf2 in
breast cancer. While MDA-MB-435 S cells expressing
Sulfatase 2 can represent a valid model to study the
effect of endogenous Sulfatase 2 in breast cancer, we
have chosen MDA-MB-231 cells as a model for our
study because they have undetectable levels of endogen-
ously produced human Sulfatase 1 or Sulfatase 2 as ana-
lyzed by RT-PCR (Fig. 1A). MDA-MB-435 S cells in
comparison have detectable endogenous expression of
Sulfatase 2 as shown in Fig. 1A. In addition, MDA-MB-
231 is an estrogen-independent cell line that does not
require exogenously added estrogen for xenograft
growth. This was an advantage in our study to focus
specifically on changes in sulfatases, because estrogen
has diverse effects on tumor phenotype and angiogenesis
[14,15]. Thus, MDA-MB-231 cells were used for gain-
of-function studies to understand their roles in breast
cancer cell phenotype. We generated MDA-MB-231
cells that stably express human Sulfatase 2 or Sulfatase
1, or a combination of both sulfatases. HSulf1 stably
transfected MDA-MB-231 cel l sw e r eu s e da sap o s i t i v e
control based on previous publication on the effect of
expression of hSulf1 in breast cancer cells [8]. Following
transfection with sulfatase constructs, expression was
confirmed by RT-PCR with specific primers (Fig. 1B). In
addition, we were interested in understanding the effect
of recombinant hSulf2 as a possible therapeutic for
breast cancer. We have expressed and purified recombi-
nant hSulf2 (rhSulf2) in the HT1080 human cell line.
Coomassie staining shows a prominent band at about
120 KDa, corresponding to rhSulf2 loaded in both lanes
(Fig. 1C). After purification, rhSulf2 was tested for activ-
ity based on its ability to convert 4-methylumbelliferyl
sulfate (4-MUS) into fluorescent 4-methylumbelliferone
as previously described [16]. The activity of hSulf2 was
relatively stable over the course of 2 days if diluted in
mouse serum, which had a protective effect on rhSulf2,
and extended its biological activity over time compared
t or h S u l f 2s t o r e di nc e l lm e d i u ma t3 7 ° C( F i g .1 D ) .
These results suggest that rhSulf2 could potentially be
used for in vivo studies due to its long lasting activity in
serum.
Modulation of MDA-MB-231 cell invasion and
proliferation by hSulf2
The effect of sulfatases in inhibiting cell invasion has
been investigated by over-expression of hSulf1 in differ-
ent cancer cells [4,8]. But, to date, recombinant human
Sulfatase 2 effect on breast cancer cells has not been
tested in vitro or in vivo. We treated MDA-MB-231
cells with different concentrations of rhSulf2 and we
observed a dose-dependent decrease in invasion through
an ECM barrier with the highest effect at 125 nM or
250 nM rhSulf2 compared to buffer control (Fig. 2A).
As a positive control we tested MDA-MB-231 cells that
were stably transfected with either hSulf1 or hSulf2.
HSulf1 was shown by Narita et al. [8] to decrease inva-
sion of MDA-MB-468 breast cancer cells. HSulf1 and
hSulf2 stably transfected MDA-MB-231 cells confirmed
previous data from MDA-MB-468 cells and our results
obtained by treating the cells with rhSulf2 also showed
inhibition of cell invasion. It is interesting to note that
when we looked at the invasion rate of MDA-MB-435
S cells, expressing endogenous Sulfatase 2, we have
observed a lower degree of invasion compared to MDA-
MB-231 cells. The lower invasion rate of MDA-MB-435
S was further suppressed by adding 250 nM rhSuf2, sug-
gesting that hSulf2 may play a role in regulating metas-
tases in breast cancer. Furthermore, rhSulf2 inhibited
invasion at a comparable rate to the known EGFR-
dependent kinase inhibitor PD 153035 [17] (Fig. 2B).
Given the role of growth factors in promoting cell pro-
liferation and knowing that sulfatases might influence
the interaction of the growth factor receptors with
signaling molecules, we tested the ability of hSulf2 to
inhibit cell proliferation in vitro.W em e a s u r e dc e l l u l a r
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expressing hSulf2 and found decreased metabolic activ-
ity and reduced proliferation without change in cell via-
bility (Fig. 2E) compared to control cells. Interestingly,
treatment of MDA-MB-231 cells with rhSulf2 inhibited
the growth of cells compared to controls (Fig. 2D) with-
out affecting cell viability (Fig. 2F), similar to the effect
of endogenously expressed hSulf2. This suggests that
hSulf2 is probably interfering with growth factor stimu-
lation of the cells, as previously demonstrated.
HSulf2 inhibits growth factor-induced ERK activation
It is speculated that sulfatases contribute to heparan sul-
fate remodeling on the tumor cell surface impairing
growth factor signaling in the cells. It has been shown
that hSulf1 in particular inhibits ERK1/2 phosphoryla-
tion through the FGF receptor. We wanted to determine
the mechanism by which hSulf2 affects cell proliferation.
MDA-MB-231 cells were treated with 250 nM rhSulf2
for 24 hours prior to stimulation with FGF2 or HB-EGF.
Cell lysates were collected before (0 min) or 15, 30, and
60 minutes following growth factor addition (Fig. 3).
Treatment with rhSulf2 led to suppressed growth factor-
induced phosphorylation of ERK1/2. Our data correlate
with previous studies using hSulf1 that demonstrate
inhibition of FGF signaling and growth both in vitro and
in vivo in human cancer cells [4,7].
Stable expression of sulfatases in MDA-MB-231 cells
inhibits in vivo tumor xenograft growth
Expression of hSulf1 in human cancer cell xenograft
in vivo inhibits tumor growth and progression [4,7]. No
studies are currently available on the effect of hSulf2 on
tumor xenograft in vivo. Therefore we tested two in vivo
xenograft protocols to determine the effects of hSulf2 on
tumor growth. As a positive control we used MDA-MB-
231 hSulf1 expressing cells. The two sulfatases were also
co-expressed to test for a cooperative effect between
hSulf1 and hSulf2. The stable transfectants were injected
subcutaneously and monitored to compare sulfatase-
expressing cells with empty vector control cells (Fig. 4).
All groups formed tumors initially and there was no sig-
nificant difference in average tumor volume at day 5.
Tumor xenografts composed of MDA-MB-231 cells sta-
bly co-expressing hSulf1 and hSulf2 (S1 + S2) demon-
s t r a t e dc o m p l e t er e g r e s s i o n( F i g .4 ,p<0 . 0 2 ) ,w i t hn o
tumors remaining by day 35 after injection. Tumor
xenograft groups expressing either hSulf1 or hSulf2
demonstrated partial regression with significant
decreases in average tumor volume (p < 0.03 and
p < 0.02 respectively). The fact that tumors co-expressing
hSulf1 and hSulf2 formed tumors initially that later
regressed suggests that a threshold of persistent sulfa-
tase activity in the tumor microenvironment may be
required for its anti-tumor activity. While MDA-MB-
231 xenograft growth rate and size varies amongst
studies reported in the literature, our tumor xenografts
were in range with those reported previously [18,19].
Tumor xenograft size variability and variable growth
rate may be due to MDA-MB-231 cell line heterogene-
ity (as opposed to clonal expansion of a single cell
population) as well as variation in strain of immuno-
compromised mouse host. NCr homozygous nude mice
have intact innate immunity, which includes anti-tumor
natural killer cell activity.
Control group tumors exhibited a significantly higher
average mitotic index as demonstrated by Ki-67 staining
(Fig. 4B, p < 0.001 and 4C). Control group tumors also
displayed higher cellular density (white arrow in Fig. 5).
Correlating with recent studies of sulfatase expression in
myeloma cells [4], our experimental tumor xenograft
groups expressing sulfatases show comparatively
increased ECM deposition and collagen (black arrows in
Fig. 5). Because of the possibility that tumor-derived sul-
fatases could impact both tumor and stromal cells, the
vascular response in the tumors was evaluated by CD31
(PECAM) antibody staining of endothelial cells, followed
by quantification of vessel area. There was no significant
Figure 1 Sulfatase expression in a human breast cancer model
and analysis of recombinant human Sulfatase 2. A) Human
breast cancer cell lines MDA-MB-231 (MB 231) and MDA-MB-435 S
(MB 435) were tested for expression of Sulfatase1 (hSulf1), Sulfatase2
(hSulf2), or b-actin by RT-PCR. B) RT-PCR was used to detect hSulf1,
hSulf2 or both sulfatase transcripts in MDA-MB-231 after stable
transfection with human sulfatase-containing plasmids. C)
Coomassie staining of SDS-PAGE gel shows a prominent band at
120 KDa corresponding to purified rhSulf2 loaded in both lanes. D)
Purified hSulf2 protein was incubated at 250 nM in medium or
mouse serum, and activity assayed over time.
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Page 5 of 11Figure 2 Sulfatase 2 decreases breast cancer cell invasion and proliferation. A) MDA-MB-231 (MB-231) and MDA-MB-435 S (MB-435) cell
invasion was assayed with treatment of recombinant hSulf2 protein compared to buffer treatment (0). Stably hSulf2 transfected cells (S2) were
also compared to control vector transfected cells for invasive ability * = p < 0.002; ** = p < 0.001; *** = p < 0.04. B) Invasion assays were
performed with MDA-MB-231 cells in the presence of the EGFR kinase inhibitor PD153035 or rhSulf2. C) For the proliferation assay, cells were
plated and collected over 4 days to test mitochondrial reductase metabolic activity using the MTT assay. Decreased MTT conversion in hSulf2
transfected cells corresponded to non-proliferating cells during this period. D) Recombinant human Sulfatase 2 protein (rhSulf2) was added to
MDA-MB-231 cells at 250 nM, and cells assayed over 3 days using the MTT assay. E) Cell viability is expressed as percent of live cells and
corresponds to data represented in panel C. F) Corresponding cell viability data for panel D; n.s. = not significant.
Figure 3 Recombinant human Sulfatase 2 inhibits growth factor-induced ERK activation. MDA-MB-231 cells were treated with 250 nM
rhSulf2 for 24 h prior to FGF (A) or HB-EGF (B) stimulation. Cell lysates were collected before growth factor addition (0 min), or 15, 30, and 60
minutes after addition for analysis of phospho-ERK1/2 and total ERK. The two phosphorylated p44 and p42 species of ERK are detected using
phospho-ERK1/2 antibodies.
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tumors in the control, hSulf1 or hSulf2 transfected
groups (data not shown). This finding correlates with
the observation in myeloma tumor xenografts that inhi-
bition of tumor xenograft formation was not dependent
on changes in microvessel density [4]. Although in vitro
cell viability was not regulated by sulfatases, the in vivo
phenotype shows tumor regression following the estab-
lishment of a small tumor, particularly with the com-
bined expression of hSulf1 and hSulf2. Thus, hSulf2
expression in tumor cells leads to a phenotype consis-
tent with cell intrinsic and localized effect to suppress
growth of tumor cells. Dai et al. postulate that restricted
sulfatase activity within the tumor microenvironment in
vivo is due to heparan sulfate remodeling on the tumor
cell surface rather than the surrounding ECM [4].
Experimental support for this model was the assembly
of an FGF2 tertiary signaling complex in the tumor
stroma but not on the surface of tumor cells [4]. This is
further supported by the fact that a restricted local
effect of Sulf1 has been shown by Ai, et al. who demon-
strated that quail Sulf1 only alters the heparan sulfate
on the cell expressing the enzyme as opposed to adja-
cent cells that lack Sulf1 expression [20].
Exogenous short term intratumoral administration of
rhSulf2 is not sufficient for inhibition of tumor xenograft
growth
As a second method to test sulfatase activity in tumor
growth, we formed xenografts with MDA-MB-231 cells
(non-transfected), and treated growing tumors by intra-
tumoral injection of rhSulf2 or buffer vehicle. RhSulf2
injections were started 2 days after cell injection, and
continued for 7 consecutive days. There was no signifi-
cant difference in average tumor volume between the
rhSulf2 treated mice or the buffer vehicle treated mice
at day 9 after tumor cell injection (Fig. 6A). The differ-
ences observed with this protocol versus the stable
transfectants may be due to lack of persistent, tumor-
derived sulfatase expression. As noted above, the source
of the sulfatase and its ability to mediate functional
enzymatic activity seems to require activity near tumor
cell surfaces. This may explain why transfected tumor
cells exhibited dramatic inhibition of tumor xenograft
growth while it was not possible to mimic these results
with exogenously administered rhSulf2 into the general
tumor environment. In addition, the variability between
individual tumor growth patterns in this experiment
could also account for lack of significant decrease in
Figure 4 Stable expression of sulfatases in MDA-MB-231 cells inhibits in vivo tumor xenograft growth. A) Average tumor volume at day
35 study endpoint for control vector transfected MDA-MB-231 cells compared with hSulf1 and hSulf2 transfected (S1+S2), hSulf1 (S1), and hSulf2
(S2) transfected cells. The average value and standard deviation are based on caliper measurements and calculated tumor volumes from the
eight mice in each group *p < 0.03. B) Average mitotic index at day 35 study endpoint for hSulf1 (S1) and hSulf2 (S2) transfected tumors in
comparison to control as determined by Ki-67 staining *p < 0.001. C) Representative fields used for quantification of mitotic index by Ki-67
staining. The scale bar represents 50 μm..
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tumor volume was additionally obtained by three-
dimensional (3D) reconstruction of the tumor by high-
resolution ultrasound scanning. As expected, control
mice not injected with cells or buffer-matrigel suspen-
sion did not develop spontaneous tumors. The control
mice injected with buffer-matrigel suspension initially
developed palpable nodules at the injection site due to
the matrigel suspension that spontaneously regressed
within 9 days (Fig. 6A). For simplicity, the control data
point is based on the eight mice included in both
control branches. These studies validate the use of ultra-
sound as a highly quantitative method to monitor 3D
growth of tumors over time. This method may be parti-
cularly useful for the tracking of tumors growing intern-
ally on or within solid organs.
Discussion and Conclusions
The results presented in this study suggest a potential
role for hSulf2 in inhibiting cancer growth and metas-
tases. We have demonstrated that cell invasion through
an ECM-enriched matrigel is strongly inhibited when
Figure 5 Histopathological features of tumor xenografts from MDA-MB-231 cells transfected with control vector, Sulfatase 1 or
Sulfatase 2. A-C) Masson’s trichrome staining of tumor xenografts. D) CD31 (PECAM) staining of tumor xenografts. The scale bar represents 400
μm for row A, 100 μm for row B, and 50 μm for rows C and D. Control group tumors exhibited higher cellular density and prominent mitotic
activity (white arrow in row C), whereas the Sulfatase 1 and Sulfatase 2 group tumors contained more connective tissue and collagen (black
arrows in rows B and C). For the tumors present, vessel density quantification of CD31 (PECAM) staining showed no significant differences
between groups. Analogous data for the transfected tumors co-expressing Sulfatase 1 and 2 are not available due to tumor regression.
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Page 8 of 11the cells are expressing hSulf2 or are in the presence
of rhSulf2, and this effect is dose-dependent. The
inhibitory effect of hSulf2 on MDA-MD-231 cells is
comparable to the one observed with the classical
EGFR-dependent kinase inhibitor PD153035. HSulf2
inhibits cell growth and proliferation of cells, and it
does so by interfering with growth factor signaling.
Until recently, investigations into the action of hSulf1
and hSulf2 focused on growth factor modulation and
angiogenesis. In the non-sulfatase expressing breast can-
cer cell line MDA-MB-468, forced expression of hSulf1
led to inhibition of angiogenesis and tumorigenesis in
xenografts [8]. While there is consensus regarding the
action of hSulf1 and hSulf2 in the desulfation of heparan
sulfate, there is controversy over whether this effect is
pro-angiogenic [6,21] or anti-angiogenic [4,6,8,10,21].
Specifically, studies in carcinoma cell lines producing
hSulf2 demonstrate that MCF-7-derived hSulf2 decreases
heparin sequestration of VEGF, FGF1 and selected che-
mokines to promote growth factor activity by prevention
of binding and dissociation of complexes that are already
bound [21]. Similarly, Sulf2 promotes angiogenesis in the
chick chorioallantoic membrane assay [6]. In contrast,
studies of other breast, pancreatic, renal, and hepatocellu-
lar carcinoma cell lines in which Sulf1 is down-regulated,
suggest that endosulfatase activity inhibits angiogenesis.
One potential explanation for this is that sulfatases may
display additional effects beyond modulation of angiogen-
esis in specific contexts.
Interestingly, hSulf2 has recently been identified as a
novel transcriptional target of the tumor suppressor
gene p53 indicating that it may be a p53 downstream
effector molecule [8]. This finding is particularly signifi-
cant in the context of mutant p53 status in MDA-MB-
231 and MDA-MB-468 cells and wild-type p53 status in
MCF-7 breast cancer cell lines [22,23]. Knockdown of
mutant p53 by RNA interference causes massive apopto-
sis in mutant p53 breast cancer cell lines but not in
wild-type p53 breast cancer cell lines, indicating that
mutant p53 may confer oncogenic potential as well as
loss of tumor suppressor activity [23]. Knock-down of
Sulf2 in MDA-MB-231 cells confers enhanced survival
Figure 6 Exogenous treatment with short course therapy of purified hSulf-2 insufficient for tumor xenograft inhibition. Athymic nude
mice were randomized into two experimental groups (n = 16 each) and injected with MDA-MB-231 cells. On day 2 after injection, intratumoral
injections were started with rhSulf2 or equivalent volume of vehicle. No significant difference was noted in average tumor xenograft volume
after short course intratumoral injections of purified rhSulf2. Average volume as estimated by high resolution 3D ultrasound scanning of tumors
at day 9 (A). Two methods for estimation of tumor size are shown in panels B-D. In the first method, width and height measurements (B) in
combination with length (C) can be used in ellipsoid volume calculations as described above. Alternatively, tumor tracings in multiple frames (C)
can be used to recreate a 3-dimensional tumor reconstruction and estimated volume (E). Given the irregular nature of these tumors, this second
method was employed for capturing aberrancies from true ellipsoid shape. In this case, ultrasound-estimated volume is ~73 mm
3 compared to
an equation-calculated volume of ~85 mm
3. This smaller volume is not surprising considering that caliper measurements include the overlying
subcutaneous tissue whereas intra-ultrasound caliper measurements measure only the tumor itself.
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independent growth [11]. Our data are consistent with
this work, because expression of hSulf2 had the opposite
phenotype in decreasing tumor cell growth. Our find-
ings extend the in vitro work to provide the first
description of in vivo breast cancer xenograft growth
inhibition by sulfatases.
Ai et al. [24] demonstrated that avian endosulfatases,
Sulf1 and Sulf2, associate with the cell membrane and
are enzymatically active on the cell surface to desulfate
HSPG. Desulfation of HSPG by endosulfatases has been
shown to impair growth factor signaling through FGF
and EGF receptors [4,7]. In this study we have demon-
strated that rhSulf2 decreases ERK1/2 phosphorylation as
previously found for hSulf1 and hSulf2. Therefore, our
data support decreased growth factor signaling as the
mechanism of inhibition of tumor growth. Combinatorial
therapy using conventional chemotherapy and hSulf2
could provide an alternative and more effective option,
although further study is needed to determine whether
hSulf2 could potentially be an effective exogenous ther-
apy for specific subtypes of breast adenocarcinoma.
While data from sulfatase-transfected tumors are pro-
mising, a detailed in vivo study is required to reproduce
these results with exogenous administration of rhSulf2.
Although short term intratumoral administration of
rhSulf2 was not efficient in inhibiting tumor growth,
our data suggest that constant production of hSulf2 is
required for a theraupeutic effect. In addition, secretion
of hSulf2 in stable transfectants from early stages of
xenograft growth may have modified the tumor cells or
microenvironment. Although we performed a pilot
study to administer rhSulf 2 by intravenous tail vein
injection, this approach was limited by the high osmo-
larity of buffer vehicle in a tail vein injection distal
enough to allow for adequate proximal intravenous
access for subsequent daily delivery (data not shown).
In addition, the concentrations of purified proteins were
not sufficiently high to allow for injection of small
enough volumes. While this could potentially be cir-
cumvented by jugular venous cannulation for central
line access, the concentration of protein accumulated at
the tumor site is predicted to be much lower than com-
pared to intratumoral injection. Development of strate-
gies for therapeutic exogenous administration of
sulfatases requires in depth pharmacokinetic analysis for
determination of volume of distribution, rate of metabo-
lism, and dose-response curves in different contexts.
Given the complexity of cellular events during malig-
nant transformation and tumor progression in addition
to the context-dependent nature of sulfatase activity, it
is not surprising that the delivery method is critical to
tumor response. Potential complicating factors to be
considered in the future include active concentrations
in the tumor microenvironment, the timing and dura-
tion of sulfatase administration, and a requirement for
tumor cell expression for intrinsic growth effect.
However, our studies provide proof of principle that
sulfatase within a human breast cancer xenograft can
lead to tumor suppression and indeed regression of
established tumors.
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